{"entity":{"id":"bpx-603","kind":"drug","name":"BPX-603","aka":[],"tldr":"BPX-603 is an autologous dual-switch CAR-T cell therapy from Bellicum Pharmaceuticals that reached phase 1 for HER2-positive solid tumours, HER2-positive gastric cancer and HER2-positive breast cancer; development has stopped.","summary":"BPX-603 is an autologous dual-switch CAR-T cell therapy (GoCAR platform) from Bellicum Pharmaceuticals. An autologous dual-switch GoCAR-T product containing both the iMC activation and CaspaCIDe safety switches, designed to target solid tumours that express HER2. Its furthest stage is phase 1, for HER2-positive solid tumours, HER2-positive gastric cancer and HER2-positive breast cancer. ClinicalTrials.gov registers it in one study linked below. Bellicum announced on 14 March 2023 that it would discontinue the phase 1/2 trials of BPX-601 and BPX-603; registry status of NCT04650451 is SUSPENDED. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Bellicum Pharmaceuticals: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1358403/000162828023010145/blcm-20221231.htm"},{"label":"Bellicum Pharmaceuticals: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1358403/000153949723002188/exh99-1.htm"},{"label":"ClinicalTrials.gov: trials of BPX-603","url":"https://clinicaltrials.gov/search?intr=BPX-603"}],"tags":["pipeline","ctgov-ingest","discontinued"],"related":[],"cancers":["metastatic-cancer","gastric-her2-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":["her2"],"drugs":[],"companies":["bellicum"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04650451"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"BPX-603","modality":"Autologous dual-switch CAR-T cell therapy (GoCAR platform)","mechanism":"An autologous dual-switch GoCAR-T product containing both the iMC activation and CaspaCIDe safety switches, designed to target solid tumours that express HER2.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bpx-603/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"gastric-her2-positive","kind":"cancer","name":"HER2-positive gastric cancer","route":"/cancers/gastric-her2-positive/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"bellicum","kind":"company","name":"Bellicum Pharmaceuticals","route":"/companies/bellicum/"}],"trial":[{"id":"nct04650451","kind":"trial","name":"Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors","route":"/trials/nct04650451/"}]}}